In 1999, a clinical trial testing the efficacy of a TNF inhibitor, Lenercept, for MS treatment had to be halted due to exacerbations of symptoms when compared to placebo-treated MS patients (20). This evidence concerns the gene TNF and myeloid sarcoma.